|
|
Blood, 1 May 2005, Vol. 105, No. 9, pp. 3465-3471.
Prepublished online as a Blood First Edition Paper on January 11, 2005; DOI 10.1182/blood-2004-06-2483.
Previous Article | Table of Contents | Next Article 
GENE THERAPY
Ex vivo culture of Fancc-/- stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy
Xiaxin Li,
Michelle M. Le Beau,
Samantha Ciccone,
Feng-Chun Yang,
Brian Freie,
Shi Chen,
Jin Yuan,
Ping Hong,
Attilio Orazi,
Laura S. Haneline, and
D. Wade Clapp
From the Department of Pediatrics, Herman B Wells Center for Pediatric Research, Section of Hematology/Oncology, University of Chicago, Chicago, IL; and the Departments of Microbiology/Immunology and Pathology, Indiana University School of Medicine, Indianapolis, IN.
Current strategies for genetic therapy using Moloney retroviruses require ex vivo manipulation of hematopoietic cells to facilitate stable integration of the transgene. While many studies have evaluated the impact of ex vivo culture on normal murine and human stem/progenitor cells, the cellular consequences of ex vivo manipulation of stem cells with intrinsic defects in genome stability are incompletely understood. Here we show that ex vivo culture of Fancc-/- bone marrow cells results in a time-dependent increase in apoptosis of primitive Fancc-/- progenitor cells in conditions that promote the proliferation of wild-type stem/progenitor cells. Further, recipients reconstituted with the surviving Fancc-/- cells have a high incidence of cytogenetic abnormalities and myeloid malignancies that are associated with an acquired resistance to tumor necrosis factor (TNF- ). Collectively, these data indicate that the intrinsic defects in the genomic stability of Fancc-/- stem/progenitor cells provide a selective pressure for cells that are resistant to apoptosis and have a propensity for the evolution to clonal hematopoiesis and malignancy. These studies could have implications for the design of genetic therapies for treatment of Fanconi anemia and potentially other genetic diseases with intrinsic defects in genome stability.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Clonal escape in Fanconi anemia: new hurdle for gene therapy?
- Johnson M. Liu
Blood 2005 105: 3387.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
M. D. Milsom, B. Schiedlmeier, J. Bailey, M.-O. Kim, D. Li, M. Jansen, A. M. Ali, M. Kirby, C. Baum, L. J. Fairbairn, et al.
Ectopic HOXB4 overcomes the inhibitory effect of tumor necrosis factor-{alpha} on Fanconi anemia hematopoietic stem and progenitor cells
Blood,
May 21, 2009;
113(21):
5111 - 5120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Saadatzadeh, K. Bijangi-Vishehsaraei, R. Kapur, and L. S. Haneline
Distinct roles of stress-activated protein kinases in Fanconi anemia type C-deficient hematopoiesis
Blood,
March 19, 2009;
113(12):
2655 - 2660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Porter and J. DeGregori
Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection
Blood,
December 1, 2008;
112(12):
4466 - 4474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Si, A. C. Pulliam, Y. Linka, S. Ciccone, C. Leurs, J. Yuan, O. Eckermann, S. Fruehauf, S. Mooney, H. Hanenberg, et al.
Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells
Blood,
December 1, 2008;
112(12):
4458 - 4465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. C. Bagby and G. Meyers
Bone Marrow Failure as a Risk Factor for Clonal Evolution: Prospects for Leukemia Prevention
Hematology,
January 1, 2007;
2007(1):
40 - 46.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Si, S. Ciccone, F.-C. Yang, J. Yuan, D. Zeng, S. Chen, H. J. van de Vrugt, J. Critser, F. Arwert, L. S. Haneline, et al.
Continuous in vivo infusion of interferon-gamma (IFN-{gamma}) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice
Blood,
December 15, 2006;
108(13):
4283 - 4287.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W. Lensch and G. Q. Daley
Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells
Blood,
April 1, 2006;
107(7):
2605 - 2612.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|